ExpreS2ion will participate in key industry and investor events
Hørsholm, Denmark, November 15, 2022 – ExpreS2ion Biotech Holding AB’s affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") will participate and hold presentations at key industry and investor events in the coming month. These include PEGS Europe Protein & Antibody Engineering Summit (November 14-16), the presentation of Q3 2022 results (November 17), and the BioStock Life Science Summit 2022 (November 29-30).
By attending relevant industry and investor events, the company aims to increase the awareness of the ExpreS2 technology platform and its exciting development pipeline, including the novel ES2B-C001 HER2-cVLP breast cancer vaccine. More information on each event and how to register is found below and on the Company’s website.
PEGS Europe - Protein & Antibody Engineering Summit, November 14-16, Barcelona, Spain
Meet ExpreS2ion’s VP of R&D and Technology, Dr. Max M. Søgaard at the largest protein & antibody engineering event in Europe. More information and registration can be found on the PEGS Europe website.
Presentation of Q3 2022 results hosted by HC Andersen Capital, November 17 at 10:00 CET, Virtual
ExpreS2ion CEO Bent U. Frandsen and CFO Keith Alexander will discuss the Q3 2022 results and answer investors’ questions. More information and registration can be found on the H.C. Andersen Capital Events website.
BioStock Life Science Summit 2022, November 30 at 14:40 CET, Medicon Village, Lund, Sweden
CEO Bent U. Frandsen will present ExpreS2ion to investors and potential investors. Registration is possible via the BioStock website.
Certified Adviser
Svensk Kapitalmarknadsgranskning AB
For further information about ExpreS2ion Biotech Holding AB, please contact:
Bent U. Frandsen, CEO
Telephone: +45 4256 6869
E-mail: buf@expres2ionbio.com
Keith Alexander, CFO
Telephone: +45 5131 8147
E-mail: ka@expres2ionbio.com
About ExpreS2ion
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. ExpreS2ion has developed a unique technology platform, ExpreS2, for fast and efficient non-clinical development and production of complex proteins for new vaccines and diagnostics. ExpreS2 is regulatorily validated for clinical supply. The platform includes functionally modified glycosylation variants for enhanced immunogenicity and pharmacokinetics. Since 2010, the Company has produced more than 500 proteins and virus-like particles (VLPs) in collaboration with leading research institutions and companies. ExpreS2ion develops novel VLP based vaccines in association with AdaptVac ApS, of which ExpreS2ion owns 34%. For additional information, please visit www.expres2ionbio.com.